Cordistronic Health Technologies is an R&D company founded in 2021 to develop medical devices for the technical standardization of complex cardiovascular surgery, as well as innovative solutions in AI-based medical image processing, diagnostic software, and healthcare IT.
2021
Founded
2
Patented Technologies
6
Industry Focus Areas
We accelerate the progress of medicine with technology and innovative inventions.
To standardize and simplify skill-dependent surgical operations through patented medical devices, and to deliver AI-driven diagnostic software that reduces physician workload and brings objective precision to chronic disease follow-up.
To become a globally recognized R&D company that brings together experts who drive change through technological solutions in medicine and shape the future of healthcare with accessible, world-class precision.
From patent grants to patient populations: the measurable scope of Cordistronic's R&D footprint.
0
Granted Patents
Across TR, US, and EU jurisdictions for EDF & ESR devices.
0
Cardiac Surgery Centers
Global TAM for EDF standardization of the David Procedure.
0.0M
MS Patients Worldwide
Beneficiaries of automated longitudinal MRI follow-up.
$0.0B
LVAD Market
Addressable market for ESR sutureless implantation ring.
Six leaders uniting cardiovascular surgery, neuroradiology, mechanical engineering, economics, and preclinical research: backed by an institutional investor partner.
Founder & CEO
Leading Cordistronic's vision to standardize complex cardiovascular surgery through patented mechanical instruments.
Co-Founder
Drives the AI radiology pillar, translating clinical neuroradiology needs into the AI-powered MS follow-up platform.
CSO · Preclinical & Clinical R&D
Leads preclinical and clinical R&D, ensuring scientific rigor across the surgical and AI product pipelines.
CFO
Oversees financial strategy, investor relations, and commercial scaling of the patent portfolio.
CIO / Software
Architects the software stack and mechanical R&D bridging engineering discipline and clinical product design.
Investor Partner
4% share, with option up to 3% additional, since November 2023.
From a 2016 patent application to multi-region IP grants and active clinical testing: explore the milestones that built Cordistronic.
…and the journey continues toward clinical deployment.
Join Cordistronic as a partner, investor, or collaborator.